S
Sandeep S. Dave
Researcher at Duke University
Publications - 146
Citations - 15780
Sandeep S. Dave is an academic researcher from Duke University. The author has contributed to research in topics: Diffuse large B-cell lymphoma & Lymphoma. The author has an hindex of 39, co-authored 124 publications receiving 14088 citations. Previous affiliations of Sandeep S. Dave include Durham University & Northwestern University.
Papers
More filters
Journal ArticleDOI
Stromal gene signatures in large-B-cell lymphomas
Georg Lenz,George E. Wright,Sandeep S. Dave,Wenming Xiao,Jonathan D. Powell,Hong Zhao,Weihong Xu,Bruce K. Tan,Neta Goldschmidt,Javeed Iqbal,Julie M. Vose,Martin Bast,Kai Fu,Dennis D. Weisenburger,Timothy C. Greiner,James O. Armitage,Alastair H. Kyle,Lorraine May,Randy D. Gascoyne,Joseph M. Connors,Gunhild Trøen,Harald Holte,Stein Kvaløy,Daan Dierickx,Gregor Verhoef,Jan Delabie,Erlend B. Smeland,Pedro Jares,A. Martinez,Armando López-Guillermo,Emili Montserrat,Elias Campo,Rita M. Braziel,Thomas P. Miller,Lisa M. Rimsza,James R. Cook,Brad Pohlman,John Sweetenham,Raymond R. Tubbs,Richard I. Fisher,Elena Hartmann,Andreas Rosenwald,German Ott,German Ott,H-K Muller-Hermelink,D Wrench,T. A. Lister,Elaine S. Jaffe,Wyndham H. Wilson,Wing C. Chan,Louis M. Staudt +50 more
TL;DR: Survival after treatment of diffuse large-B-cell lymphoma is influenced by differences in immune cells, fibrosis, and angiogenesis in the tumor microenvironment, and a multivariate model created from three gene-expression signatures predicted survival both in patients who received CHOP and patients who receive R-CHOP.
Journal ArticleDOI
Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells
Sandeep S. Dave,George E. Wright,Bruce K. Tan,Andreas Rosenwald,Andreas Rosenwald,Randy D. Gascoyne,Wing C. Chan,Richard I. Fisher,Rita M. Braziel,Lisa M. Rimsza,Thomas M. Grogan,Thomas P. Miller,Michael LeBlanc,Timothy C. Greiner,Dennis D. Weisenburger,James C. Lynch,Julie M. Vose,James O. Armitage,Erlend B. Smeland,Stein Kvaløy,Harald Holte,Jan Delabie,Joseph M. Connors,Peter M. Lansdorp,Qin Ouyang,T. Andrew Lister,Andrew Davies,Andrew J. Norton,H. Konrad Muller-Hermelink,German Ott,Elias Campo,Emilio Montserrat,Wyndham H. Wilson,Elaine S. Jaffe,Richard M. Simon,Liming Yang,John Powell,Hong Zhao,Neta Goldschmidt,Michael Chiorazzi,Louis M. Staudt +40 more
TL;DR: The length of survival among patients with follicular lymphoma correlates with the molecular features of nonmalignant immune cells present in the tumor at diagnosis.
Journal ArticleDOI
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach,Richard R. Furman,Ta-Ming Liu,Hatice Gulcin Ozer,Marc Zapatka,Amy S. Ruppert,Ling Xue,Daniel Hsieh Hsin Li,Susanne M. Steggerda,Matthias Versele,Sandeep S. Dave,Jenny Zhang,Ayse Selen Yilmaz,Samantha Jaglowski,Kristie A. Blum,Arletta Lozanski,Gerard Lozanski,Danelle F. James,Jacqueline C. Barrientos,Peter Lichter,Stephan Stilgenbauer,Joseph J. Buggy,Betty Y. Chang,Amy J. Johnson,John C. Byrd +24 more
TL;DR: Functional analysis showed that the C481S mutation of BTK results in a protein that is only reversibly inhibited by ibrutinib, which underscores the importance of the B-cell-receptor pathway in the mechanism of action of ibrUTinib in CLL.
Journal ArticleDOI
Frequent Engagement of the Classical and Alternative NF-κB Pathways by Diverse Genetic Abnormalities in Multiple Myeloma
Christina M. Annunziata,R. Eric Davis,Yulia N. Demchenko,William T. Bellamy,Ana Gabrea,Fenghuang Zhan,Georg Lenz,Ichiro Hanamura,George E. Wright,Wenming Xiao,Sandeep S. Dave,Elaine M. Hurt,Bruce K. Tan,Hong Zhao,Owen W. Stephens,Madhumita Santra,David R. Williams,Lenny Dang,Bart Barlogie,John D. Shaughnessy,W. Michael Kuehl,Louis M. Staudt +21 more
TL;DR: It is demonstrated that addiction to the NF-kappaB pathway is frequent in myeloma and suggest that IKKbeta inhibitors hold promise for the treatment of this disease.
Journal ArticleDOI
Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
Georg Lenz,George E. Wright,N. C. Tolga Emre,Holger Kohlhammer,Sandeep S. Dave,R. Eric Davis,Shannon A. Carty,Lloyd T. Lam,Arthur L. Shaffer,Wenming Xiao,John Powell,Andreas Rosenwald,German Ott,German Ott,Hans Konrad Müller-Hermelink,Randy D. Gascoyne,Joseph M. Connors,Elias Campo,Elaine S. Jaffe,Jan Delabie,Erlend B. Smeland,Lisa M. Rimsza,Richard I. Fisher,Dennis D. Weisenburger,Wing C. Chan,Louis M. Staudt +25 more
TL;DR: High-resolution, genome-wide copy number analysis coupled with gene-expression profiling provides genetic evidence that the DLBCL subtypes are distinct diseases that use different oncogenic pathways.